The Medical Letter on Drugs and Therapeutics
Vonvendi - Recombinant von Willebrand Factor (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved intravenously administered recombinant von Willebrand factor (Vonvendi - Shire) for adults with von Willebrand disease (VWD) who require on-demand treatment and control of bleeding episodes. It is the first recombinant von Willebrand factor (VWF) product to become available in the US.

VON WILLEBRAND DISEASE — VWD is the most common inherited bleeding disorder; the prevalence of symptomatic VWD in the general population is about 0.1%, divided equally among men and women.1 It is characterized by a deficiency of VWF and, in severe cases, of factor VIII, the antihemophilic clotting factor. VWF is synthesized in endothelial cells and megakaryocytes; it mediates platelet activation and adhesion in flowing blood after vascular injury and stabilizes factor VIII.

VWD is subdivided into 3 types: type 1 is characterized by mild to moderate reductions in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vonvendi - Recombinant von Willebrand Factor (online only)
Article code: 1521f
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian